Evolution of beta-blockers: from anti-anginal drugs to ligand-directed signalling

Jillian G Baker, Stephen J Hill, Roger J Summers

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Sir James Black developed beta-blockers, one of the most useful groups of drugs in use today. Not only are they being used for their original purpose to treat angina and cardiac arrhythmias, but they are also effective therapeutics for hypertension, cardiac failure, glaucoma, migraine and anxiety. Recent studies suggest that they might also prove useful in diseases as diverse as osteoporosis, cancer and malaria. They have also provided some of the most useful tools for pharmacological research that have underpinned the development of concepts such as receptor subtype selectivity, agonism and inverse agonism, and ligand-directed signalling bias. This article examines how beta-blockers have evolved and indicates how they might be used in the future.
Original languageEnglish
Pages (from-to)227 - 234
Number of pages8
JournalTrends in Pharmacological Sciences
Volume32
Issue number4
DOIs
Publication statusPublished - 2011

Cite this

@article{5f0733668f7e49fdb81953a49567fd18,
title = "Evolution of beta-blockers: from anti-anginal drugs to ligand-directed signalling",
abstract = "Sir James Black developed beta-blockers, one of the most useful groups of drugs in use today. Not only are they being used for their original purpose to treat angina and cardiac arrhythmias, but they are also effective therapeutics for hypertension, cardiac failure, glaucoma, migraine and anxiety. Recent studies suggest that they might also prove useful in diseases as diverse as osteoporosis, cancer and malaria. They have also provided some of the most useful tools for pharmacological research that have underpinned the development of concepts such as receptor subtype selectivity, agonism and inverse agonism, and ligand-directed signalling bias. This article examines how beta-blockers have evolved and indicates how they might be used in the future.",
author = "Baker, {Jillian G} and Hill, {Stephen J} and Summers, {Roger J}",
year = "2011",
doi = "10.1016/j.tips.2011.02.010",
language = "English",
volume = "32",
pages = "227 -- 234",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier",
number = "4",

}

Evolution of beta-blockers: from anti-anginal drugs to ligand-directed signalling. / Baker, Jillian G; Hill, Stephen J; Summers, Roger J.

In: Trends in Pharmacological Sciences, Vol. 32, No. 4, 2011, p. 227 - 234.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Evolution of beta-blockers: from anti-anginal drugs to ligand-directed signalling

AU - Baker, Jillian G

AU - Hill, Stephen J

AU - Summers, Roger J

PY - 2011

Y1 - 2011

N2 - Sir James Black developed beta-blockers, one of the most useful groups of drugs in use today. Not only are they being used for their original purpose to treat angina and cardiac arrhythmias, but they are also effective therapeutics for hypertension, cardiac failure, glaucoma, migraine and anxiety. Recent studies suggest that they might also prove useful in diseases as diverse as osteoporosis, cancer and malaria. They have also provided some of the most useful tools for pharmacological research that have underpinned the development of concepts such as receptor subtype selectivity, agonism and inverse agonism, and ligand-directed signalling bias. This article examines how beta-blockers have evolved and indicates how they might be used in the future.

AB - Sir James Black developed beta-blockers, one of the most useful groups of drugs in use today. Not only are they being used for their original purpose to treat angina and cardiac arrhythmias, but they are also effective therapeutics for hypertension, cardiac failure, glaucoma, migraine and anxiety. Recent studies suggest that they might also prove useful in diseases as diverse as osteoporosis, cancer and malaria. They have also provided some of the most useful tools for pharmacological research that have underpinned the development of concepts such as receptor subtype selectivity, agonism and inverse agonism, and ligand-directed signalling bias. This article examines how beta-blockers have evolved and indicates how they might be used in the future.

UR - http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21429598

U2 - 10.1016/j.tips.2011.02.010

DO - 10.1016/j.tips.2011.02.010

M3 - Article

VL - 32

SP - 227

EP - 234

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 4

ER -